ZBIO SEC Filings: 8-K, 10-Q, S-3 & 424B – Zenas BioPharma

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 16, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Zenas BioPharma Files New Prospectus Supplement for At-the-Market Offering of Up to $200 Million in Common Stock

Nov 6, 2026

8-K

Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

Nov 5, 2026

8-K

Zenas BioPharma Announces New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium

Oct 13, 2026

8-K

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 13, 2026

8-K

Zenas BioPharma Reports Q1 2026 Financial Results and Corporate Pipeline Updates

May 13, 2026

8-K

Zenas BioPharma Completes $200 Million Convertible Notes Offering and $100 Million Equity Offering

Mar 31, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* November 2026 ATM | Offering amount: $200,000,000 | Bank: Jefferies LLC

Nov 6, 2026

424B5

REGISTERED OFFERING

Mar 30, 2026

424B5

REGISTERED OFFERING

Mar 30, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Jefferies, Evercore ISI, Citigroup, Guggenheim Securities

Mar 26, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Jefferies, Evercore ISI, Citigroup, Guggenheim Securities, Wedbush PacGrow

Mar 26, 2026

424B7

SHARE RESALE REGISTRATION - COMMON STOCK | Shares: 8,533

Jan 28, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

SHARE RESALE REGISTRATION

Sep 11, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Sep 11, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Mar 27, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Mar 27, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Mar 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 16, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 16, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 16, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

Xencor Inc (Filed by)

Nov 5, 2026

SCHEDULE 13G

BlackRock, Inc. (Filed by)

Oct 27, 2026

SCHEDULE 13G

WELLINGTON MANAGEMENT GROUP LLP (Filed by)

Sep 8, 2026

InnoCare Pharma Inc. (Reporting)

Sep 8, 2026

SCHEDULE 13G/A

InnoCare Pharma Inc. (Filed by)

Sep 8, 2026

Oliger Christy J. (Reporting)

Sep 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 13, 2024

CORRESP

Form CORRESP - Correspondence

Sep 10, 2024

CORRESP

Form CORRESP - Correspondence

Sep 10, 2024

CORRESP

Form CORRESP - Correspondence

Aug 27, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jul 24, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jul 5, 2024

Zenas BioPharma, Inc. ZBIO · SEC Filings